Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myocardin is a potent, tissue-restricted transcriptional coactivator encoded by the MYOCD gene, primarily expressed in cardiac and smooth muscle cells[1][4]. It functions by binding to serum response factor (SRF) and activating the expression of genes essential for cardiac and smooth muscle differentiation, including those containing CArG box elements[1][3]. Myocardin is considered a master regulator of smooth muscle cell identity and contractile phenotype, able to induce smooth muscle gene expression even in non-muscle cells and repress the skeletal muscle differentiation program by inhibiting skeletal muscle regulators such as MyoD and myogenin[4][5]. Genetic variants in MYOCD can cause congenital disorders, such as megabladder, and are implicated in cardiovascular developmental abnormalities[2]. Myocardin's precise regulation is essential for vascular homeostasis, and its dysregulation has been implicated in a range of vascular and developmental diseases[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myocardin (MYOCD).